Clinical Trials Browser

Phase 1 × Hematologic Neoplasms × Rituximab × Clear all

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Hematologic Neoplasms

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT02367196 2021-08-12

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Phase 1 Completed

60 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT04243434 2020-04-16

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Phase 1 Unknown

56 enrolled

Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

NCT01471067 2017-04-28

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Phase 1 Completed

33 enrolled

LymphoidMyeloidOther hematologic neoplasm

Pathologic Complete Response, Histiocytosis, Langerhans-Cell, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Philadelphia Chromosome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00824135 2017-01-02

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Phase 1 Completed

34 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT01871675 2016-07-11

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Phase 1 Completed

48 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT00068315 2013-09-30

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Completed

18 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Clinical Trials

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia